Core Viewpoint - Merck anticipates a non-risk adjusted commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug [1] Company Summary - Merck expects significant financial potential from the collaboration with Cidara Therapeutics, indicating confidence in the drug's market viability [1] Industry Summary - The flu drug market may see increased competition and innovation, particularly with the introduction of new experimental treatments like that from Cidara Therapeutics [1]